© 2020 © 2020 Genprex Inc. All Rights Reserved.
Genprex’s President and Chief Operating Officer, Julien Pham, MD, MPH, will lead the Company’s presentation and, along with Rodney Varner, the Company’s Chief Executive Officer, will be available for one-on-one investor meetings.
The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.
The company announced a registered direct offering of 3,167,986 shares of its common stock at a price to the public of $0.40 per share, for gross proceeds of approximately $1.26 million prior to deduction of commissions and offering expenses payable by Genprex.
AUSTIN, Texas & CAMBRIDGE, Mass.— (November 4, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month.
Each patient’s cancer is unique, but there are some preventive efforts that can be made to lower the risk of getting lung cancer….
AUSTIN, Texas & CAMBRIDGE, Mass.— (October 9, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will be presenting at the inaugural MicroCap Rodeo Investor Conference in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be available for one-on-one investor meetings….
AUSTIN, Texas & CAMBRIDGE, Mass.— (October 7, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy.
A recently published paper by researchers in Australia, Spain and Austria supports the belief that non-viral delivery could be safer for patients than viral vectors and could speed up the production time while reducing the costs of production….
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 18, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the Singular Research Midwestern Values Conference on September 19, 2019 via webcast.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s webcast presentation. …
A direct target of miR-138, TUSC2 mimics miR-138 knockdown
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 11, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options….
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 5, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it will present at the H.C. Wainwright 21stAnnual Global Investment Conference on September 9, 2019 in New York City.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be available for one-on-one meetings. …
AUSTIN, Texas & CAMBRIDGE, Mass.— (September 3, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.
These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website….